Teclistamab Production Cost Reports

The report provides a detailed analysis essential for establishing a teclistamab production plant. It encompasses all critical aspects necessary for teclistamab production, including the cost of teclistamab production, teclistamab plant cost, teclistamab production costs, and the overall teclistamab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a teclistamab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Teclistamab is used to treat advanced multiple myeloma cancer in adults. It is utilised in cases where at least 3-4 prior therapies have failed, including proteasome inhibitors, immunomodulators, and anti-CD38 antibodies like daratumumab. It binds BCMA on myeloma cells and CD3 on T-cells, redirecting the patient's immune system to attack and destroy cancer plasma cells through natural killing mechanisms. It is given subcutaneously after step-up doses to reduce cytokine release syndrome risk and shows 60%+ response rates in heavily pretreated patients where other options fail. Its common side effects include fever, cytokine release syndrome, muscle and joint pain, injection site reactions, fatigue, upper respiratory infections, nausea, etc.

The market for teclistamab is influenced by rising multiple myeloma cases around the globe. The strong clinical trial results in heavily pretreated patients and growing preference for bispecific antibodies over CAR-T because of production and access issues boost its demand. Also, label expansions into earlier treatment lines through ongoing combination studies fuel its market. The industrial teclistamab procurement is influenced by high drug pricing, requiring substantial payer discounts for cost-effectiveness. Other factors like mandatory hospital monitoring protocols for cytokine release syndrome and neurotoxicity risks, and limited production capacity from Janssen creating supply constraints impacts its sourcing.

Raw Material for Teclistamab Production

According to the teclistamab production plant project report, the key raw materials used in the production of teclistamab include Chinese hamster ovary (CHO) cells and serum-free cell culture media.

Production Process of Teclistamab

The extensive teclistamab production cost report consists of the following major industrial production process:

1. From Chinese hamster ovary (CHO) cells: The teclistamab is manufactured through a recombinant process involving production of two parental monoclonal antibodies in mammalian cell lines using serum-free suspension cultures. These antibodies undergo cell harvest by filtration, purification via multiple chromatography steps, viral inactivation and filtration, and then controlled reduction-oxidation to form the bispecific heterodimer. The drug substance is finalised by pooling, ultrafiltration, diafiltration, and formulation to give teclistamab.

Teclistamab is a bispecific IgG4 monoclonal antibody (teclistamab-cqyv) engineered via Fab-arm exchange to target BCMA on myeloma cells and CD3ε on T cells. It has a chemical formula of C6383H9847N1695O2003S40 and an average molecular weight of 146 kDa. It appears as a colourless to slightly opalescent and yellowish solution that is stable at 2-8 degrees Celsius for 3 months post-reconstitution under refrigerated conditions. It shows subcutaneous bioavailability of 69-72%, steady-state volume of distribution 5.63 L and  Tmax around 139 hours initially (72 hours at steady-state). It has proportional pharmacokinetics over 0.08-3 mg/kg doses and target-mediated clearance, reducing with accumulation.